Search

Displaying results 961 - 970 of 2872 in total
  1. Drug

    Selpercatinib

    go.drugbank.com/drugs/DB15685
    ApprovedInvestigational

    Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  2. Drug

    PF-06821497

    go.drugbank.com/drugs/DB14799
    Investigational

    PF-06821497 is under investigation in clinical trial NCT03460977 (PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma).

  3. Drug

    Elacestrant

    go.drugbank.com/drugs/DB06374
    ApprovedInvestigational

    [A256828,A256863,L44948] Other types of endocrine therapy, such as selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs), may lead to drug resistance over time; therefore, the use

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  4. Drug

    PF-05089771

    go.drugbank.com/drugs/DB14856
    Investigational

    PF-05089771 is under investigation in clinical trial NCT01529671 (A Safety And Tolerability Study Of PF-05089771 In Healthy Subjects And In Subjects With Otseoarthritis Of The Knee).

  5. Drug

    Orphenadrine

    go.drugbank.com/drugs/DB01173
    ApprovedInvestigational

    A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm.

    Mixtures: Norgesic 35 mg/450 mg TablettenCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Inhibitors
  6. Drug

    DP-VPA

    go.drugbank.com/drugs/DB05821
    Investigational

    DP-VPA is D-Pharm's proprietary lipid modified version of valproic acid (VPA) that demonstrate that DP-VPA is well-tolerated in patients with resistant epilepsy and has a marked effect on reducing seizure frequency.

  7. Drug

    Fiboflapon

    go.drugbank.com/drugs/DB06346
    Investigational

  8. Drug

    Osemozotan

    go.drugbank.com/drugs/DB05339
    Experimental

    MN-305 is a novel, potent and highly selective serotonin 5-HT1A receptor agonist under development by MediciNova for the treatment of anxiety disorders beginning with Generalized Anxiety Disorder (GAD).

  9. Drug

    Neovastat

    go.drugbank.com/drugs/DB05387
    Investigational

    Neovastat is a naturally occurring anti-angiogenic compound, extracted from cartilage, with multiple anti-angiogenic mechanisms of action that provide broad therapeutic potential for a number of diseases. It is currently in international...

  10. Drug

    PF-05180999

    go.drugbank.com/drugs/DB14885
    Investigational

    PF-05180999 is under investigation in clinical trial NCT01530529 (A Study to Assess the Relative Bioavailability of a Modified-Release Formulation of PF-05180999).